Ireland’s Dublin-based biotech company Nuritas secured €40 million in new investment through its latest financing round.

Nuritas, a biotech company founded in 2014 by Dr. Nora Khaldi, has raised €40 million in funding, bringing its total amount raised to over €100 million. The funding was led by M&G Investments’ Catalyst strategy, which supports businesses addressing global climate or social challenges. Other investors include McWin Capital Partners and Enterprise Ireland. The funds will be used to scale operations, expand the global customer base, and reach more consumers worldwide. Nuritas has developed a proprietary AI platform called Magnifier, which discovers and develops bioactive peptides for use in food, supplements, cosmetics, and other products. The company already has three commercialized products, including PeptiStrong, PeptiYouth, and PeptiPump, with plans to release two new products in 2025. Nuritas’ peptides have attracted partnerships with major companies like Givaudan, Nestlé, Mars, and Sumitomo Corporation. The company aims to improve lives by creating ingredients addressing global health challenges, and has a science-first approach to ingredient discovery. Two board members, Alex Seddon and Henry McGovern, are joining the company as part of the funding round.